Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 55,795 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $1.43, for a total value of $79,786.85. Following the completion of the transaction, the director owned 4,076,920 shares in the company, valued at $5,829,995.60. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Luke Evnin also recently made the following trade(s):

• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $77,876.01.
• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $93,685.76.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total value of $72,696.28.
• On Monday, October 27th, Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $80,262.08.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL remained flat at $1.31 during trading hours on Monday. 712,892 shares of the company’s stock traded hands, compared to its average volume of 494,803. The stock has a market cap of $59.91 million, a PE ratio of -0.80 and a beta of 0.73. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.52. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. The company’s 50-day moving average is $1.62 and its 200 day moving average is $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. On average, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics in the second quarter valued at approximately $28,000. Vontobel Holding Ltd. acquired a new position in Werewolf Therapeutics in the first quarter valued at approximately $34,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics in the second quarter valued at approximately $48,000. Nuveen LLC acquired a new position in Werewolf Therapeutics in the first quarter valued at approximately $71,000. Finally, AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the first quarter valued at approximately $79,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HOWL has been the subject of a number of research analyst reports. Bank of America reduced their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup reaffirmed a “buy” rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. Finally, Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Werewolf Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.